Signal transducer and activator of transcription 3 (STAT3) is a member of the family of latent cytoplasmic transcriptional factors that could regulate cell proliferation, survival, and development. It has been reported that Twist is a target gene of STAT3, and STAT3/Twist signaling plays an important role in regulating cancer progress. Here, to explore whether 8-bromo-7-methoxychrysin (BrMC) inhibits liver cancer stem-like cell (LCSLC) properties via disrupting STAT3/Twist signaling, we cultured SMMC-7721 cells in vitro, and evaluated the effects of BrMC on the stemness of spheroids by determining the sphere-forming capability and migration. The sphere formation assay results showed a concentration-dependent decrease of sphere-forming capacity in LCSLCs (P < 0.05) treated with different concentrations of BrMC. Wound-healing assays results demonstrated a concentration-dependent decline in cell migration of LCSLCs treated with different concentrations of BrMC. In addition, CD133, CD44, and ALDH1 levels were decreased in LCSLCs treated with BrMC. Treatment with different concentrations of BrMC also reduced the expressions of p-STAT3 and Twist1 proteins. The effect of BrMC was substantially enhanced by co-treatment with JSI-124, a specific inhibitor of STAT3. Ectopic expression of Twist1 attenuated the inhibitory effects of BrMC on sphere formation, migration, and expression of the markers in LCSLCs. However, it had no affect on p-STAT3 expression in LCSLCs. These results demonstrated that BrMC inhibits the stemness of LCSLCs originated from SMMC-7721 cell line by inhibiting STAT3/ Twist signal axis.
Introduction
Hepatocellular carcinoma (HCC) ranks the third in cancer-related deaths worldwide [1, 2] . Surgical resection combined with chemotherapy is the mainstay of treatment for HCC [3] . Despite major therapeutic advances, the overall recurrence of HCC is >70%, underscoring the need for effective interventions [3] . The cancer stem cells (CSCs) self-renew and differentiate into diverse cell populations triggering cancer growth and recurrence [4, 5] . Analysis of the biology of HCC CSCs may lead to the development of novel therapeutic strategies.
HCC cell lines have been used to characterize cells with stem cell properties [4, 6] . Liver CSC fractions were successfully enriched in CD133 or/and CD44 phenotypes [6] . However, these proteins which mediate embryonic and somatic stem cell function and embryonic development lack specificity for liver CSCs [4] . Cao et al. [4] found that spheroids from HCC cell lines cultured in stem cell-conditioned media exhibit liver cancer stem-like cells (LCSLCs) properties.
Fruits and vegetables have been shown to be able to reduce the risk of malignancy [7] . Intake of plant-based diet provides dietary phenolics, especially flavonoids with potential anti-carcinogenic activities [8] . Chrysin (5,7-dihydroxyflavone, ChR) is a natural flavone exists in plants, honey, and propolis. It induces apoptosis in HCC cells [9] . Our previous results showed that the inhibitory effect of 8-bromo-7-methoxychrysin (BrMC) on the colon cancer cell line HT-29 and the gastric cancer cell line SGC-7901 was stronger than that of ChR [10] . Our recent studies further demonstrated that BrMC significantly suppressed liver CSCs [11, 12] . However, the underlying molecular mechanisms were not fully understood.
Twist is a transcriptional factor mediating mesodermal, myoblast, and osteoblast differentiation [13] . The Twist protein levels are increased in advanced tumors, suggesting poor prognosis in HCC [14] . Furthermore, increased Twist expression in cancer cells induces metastasis, epithelial-to-mesenchymal transition (EMT), cell survival, angiogenesis, and chemoresistance [13, 14] . Our previous studies showed that BrMC inhibits liver CSCs by down-regulating Twist expression [11] . However, the molecular mechanism underlying the modulation of upstream regulators of Twist by BrMC in LCSLCs is unclear.
Signal transducer and activator of transcription 3 (STAT3) induced by cytokines and growth factors is involved in signal transduction from the cell surface to the nucleus [15] . Activated STAT3 in cancer cells regulates the expression of genes involved in self-renewal, cell migration, and oncogenesis [16] . Cheng et al. [17] demonstrated that STAT3 targets Twist transcription [17] . Recently, using JSI-124, a selective inhibitor of STAT3, we demonstrated that BrMC inhibited the LCSLC-like features in SMMC-7721 cells by inhibiting STAT3 activation [5] . However, whether BrMC regulates the STAT3/Twist signal axis in LCSLCs derived from SMMC-7721 cells is unknown. In this study, we incubated SMMC-7721 cells with stem cell-conditioned cultures to induce spheroid formation and investigated the effect of BrMC on STAT3/Twist signaling of LCSLCs generated from SMMC-7721 cell line.
Materials and Methods

Reagents and antibodies
BrMC was synthesized as previously reported [10] and dissolved in Dulbecco's modified Eagle's medium (DMEM) medium containing 99.9% dimethyl sulfoxide to a final concentration of 0.1%.
Antibodies against CD133, CD44, ALDH1, STAT3, and Twist1 were from Abcam (Burlingame, USA) and used at the dilution of 1:2000. Antibodies against p-STAT3 (Tyr 705) and β-actin were from Santa Cruz Biotechnology (Santa Cruz, USA) and used at the dilution of 1:1000 and 1:2000, respectively. Horseradish peroxidaseconjugated anti-rabbit and anti-mouse immunoglobulin G (IgG) secondary antibodies were purchased from Beyotime Institute of Biotechnology (Haimen, China) and used at the dilution of 1:2000.
Cell line and sphere culture
Human HCC SMMC-7721 cells were obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). Cells were layered single in high-glucose DMEM supplemented with 10% fetal bovine serum, 100 IU/ml penicillin G, and 100 μg/ml streptomycin, and incubated in a humidified atmosphere of 5% CO 2 at 37°C.
Cells were treated to remove serum, and incubated with serum-free DMEM/F12 (Invitrogen, Carlsbad, USA) containing 100 IU/ml penicillin, 100 μg/ml streptomycin, 20 ng/ml recombinant human epidermal growth factor (hrEGF; Invitrogen), 20 ng/ml recombinant human basic fibroblast growth factor (hrbFGF; Invitrogen), 2% B27 (Invitrogen), 0.4% bovine serum albumin (BSA), and 4 μg/ml insulin (Invitrogen). The cells were subsequently incubated in ultra low attachment six-well plates (Corning Inc., Corning, USA), at a density of 20,000 cells/well.
Cell viability assay
To assess whether BrMC inhibits SMMC-7721 cell viability, CCK-8 assay was preformed using a cell counting kit (Dojindo, Tokyo, Japan), according to the manufacturer's instructions. For CCK-8 assay, cells were seeded in 96-well plates (5000 cells/well), and cultured for 24 h, and then incubated with different concentrations of BrMC (0.1, 0.3, and 1.0 μM) for 24 h.
Spheroid formation assay
The spheroids were obtained through gentle centrifugation (200 g) and digested with trypsin-ethylenediaminetetraacetic acid (EDTA), followed by mechanical disruption with a pipette. The single cells were centrifuged to remove the enzyme, and were transferred to a serum-free medium to induce spheres. The third-generation spheroids were used as LCSLCs.
Single cells with potential for transformation into new spheroids were cultured in ultra low attachment 24-well plates at a density of 1000 cells/well to generate new spheroids. When the tumor sphere was formed after 2 days, different concentrations of BrMC (0.1, 0.3, and 1.0 μM) or JSI-124 or both of them was added. And after exposure to compounds for 24 h, the cell medium was changed to serum-free DMEM/F12 containing 100 IU/ml penicillin, 100 μg/ml streptomycin, 20 ng/ml hrEGF, 20 ng/ml hbFGF, 2% B27, 0.4% BSA, and 4 μg/ml insulin . The number of tumor spheroid was counted under an invert microscope (Olympus, Tokyo, Japan) after 6 days of culture. The efficiency of spheroid formation was calculated as a fraction of the total number of spheroids generated by the number of live cells seeded, and multiplied by 100.
Wound-healing assay
Cells (1 × 10 5 cells/well) were incubated with growth medium in 24-well plates for 48 h. The complete monolayer of cells was scratched with a standard 200-μl plastic tip. And then the cells were cultured with serum-free medium for 24 h. Migration and cell movement in the scratch area was visualized under a phase-contrast microscope (Olympus) after 24 h. Image pro-plus 6.0 was used to calculate the migrating ratio: migrating ratio = (average width of linear wound at 0 h − average width of linear wound at 24 h)/average width of linear wound at 0 h. Each experiment was performed at least three times.
Viral infection
The adenoviruses expressing green fluorescent protein (GFP) or Twist1 were obtained from Hanbio Biothechnology Co. Ltd (1.0 ml, 1 × 10 11 PFU/ml; Shanghai, China). The third-generation spheroids were transduced with Ad-expressing Twist1 (2 × 10 8 PFU) or Ad-
Western blot analysis
Cells were washed with phosphate buffered saline (PBS) and admixed with 1 ml of lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.2 mM EDTA, 0.2% NP-40, 10% glycerol, 1 M β-Mercaptoethanol (β-Me), 1 μg/ml trasylol, 0.5 μg/ml leupeptin, 0.1 mM Na 3 VO 4 , 0.5 mM 4-nitrophenylphosphate (4NPP), 0.5 mM NaF, and protease inhibitors. After incubation for 20 min at 4°C, the cells were centrifuged at 13,200 g for 5 min at 4°C to obtain whole cell extracts. Bradford assay (Bio-Rad Laboratories, Hercules, USA) was used to determine the protein content. Proteins were resolved with 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, USA). The protein membrane was incubated overnight at 4°C with the primary antibodies after blocking with 5% (w/v) skim milk in PBS contained 1‰Tween-20. The membrane was washed four times and incubated with horseradish peroxidase-conjugated goat anti-mouse IgG antibody or goat antirabbit IgG antibody for 1 h. The signal was detected using enhanced chemiluminescence kit (Amersham Biosciences, Piscataway, USA).
Statistical analysis
Data were analyzed using SPSS 20.0 for Windows (SPSS Inc, Chicago, USA). Data were expressed as the mean ± SD, and subject to one-way ANOVA. First, the homogeneity of variance was determined, and all pairwise comparisons between the groups were analyzed using least significant difference (LSD) method. In the event of incomplete variance, the control and the experimental groups were subject to Tukey's test. Significance was determined by P < 0.05. Each experiment was performed at least three times and all of the data were the average of three independent experiments.
Results
BrMC inhibited the stemness of LCSLCs from SMMC-7721 cells
Stem-like cells were enriched from HCC SMMC-7721 cell line as spheroids in a clear serum-free stem cell medium. As shown in Fig. 1A , the first-generation spheroids were used to generate secondgeneration, and subsequently third-, fourth-, and fifth-generation spheroids. These spheroids were passaged >10 times. Single cells derived from second-generation spheroids represent self-renewing cells, which were propagated as LCSLCs. SMMC-7721 cells and the third-generation spheroids were treated with BrMC (0.1, 0.3, and 1.0 μM) for 24 h. CCK-8 assay was preformed to measure the effect of BrMC on SMMC-7721 cell viability, and as shown in Fig. 1B , BrMC had no significant effect on SMMC-7721 cell viability. When the tumor sphere was formed after 2 days, different concentrations of BrMC (0.1, 0.3, and 1.0 μM) were added. Exposure to BrMC (0.1, 0.3, and 1.0 μM) for 24 h decreased the spheroid formation of LCSLCs, in a concentration-dependent manner (P < 0.05) (Fig. 1C) . In addition, BrMC reduced the migration rates of LCSLCs (Fig. 1D) . Obviously, BrMC induced a dose-dependent decrease in the expression of stem cell proteins (CD133, CD44, and ALDH1, P < 0.05; Fig. 1E ). These results suggested that BrMC could suppress the properties of LCSLCs specificity.
JSI-124 and BrMC cooperatively inhibited the stemness of LCSLCs from SMMC-7721 cells
Spheroid-forming assay showed that BrMC (0.1 μM) and JSI-124 (0.1 μM) alone lowered the spheroid-forming rates of LCSLCs from SMMC-7721 cell line ( Fig. 2A ; P < 0.05). Co-treatment with BrMC (0.1 μM) and JSI-124 (0.1 μM) cooperatively reduced the spheroidforming capacity of LCSLCs ( Fig. 2A) . Figure 2B illustrated the inhibition of cell migration by BrMC (0.1 μM) and JSI-124 (0.1 μM) alone, and with the combination treatment. Furthermore, treatment with BrMC (0.1 μM) and JSI-124 (0.1 μM) alone reduced the expressions of CD133, CD44, and ALDH1, and significantly with the combination treatment (P < 0.05; Fig. 2C ). These results suggested that the effect of BrMC was similar to that of JSI-124.
Overexpression of Twist1 decreased the inhibition of stemness in LCSLCs
As shown in Fig. 3 , Twist1 gene transduction increased spheroid formation, cell migration and expression of stem cell proteins, and significantly attenuated the inhibition by BrMC (0.1 μM) on spheroid formation, cell migration and expression of stem cell proteins (P < 0.05). These results further confirm that BrMC inhibited stem cell features of LCSLCs via down-regulation of Twsit1 expression. 
Identification of STAT3/Twist signal axis during the inhibition of stemness by BrMC
To investigate the role of BrMC in STAT3 activity and Twist1 protein expression, the effects of various concentrations of BrMC on the expression of p-STAT3 and Twist1 was determined. As shown in Fig. 4A , BrMC reduced the levels of p-STAT3 and Twist1, at specific concentrations (P < 0.05). BrMC and JSI-124 at individual concentrations of 0.1 μM reduced the expressions of p-STAT3 and Twist1. Co-treatment of BrMC and JSI-124 at a concentration of 0.1 μM each decreased the production of LCSLCs from SMMC-7721 cells (Fig. 4B) .These results suggested that both BrMC and JSI-124 inhibited STAT3 activity and Twist1 expression. Twist1 gene transduction attenuated the decrease in Twist1 protein expression by BrMC (0.1 μM), but not that of p-STAT3 expression (Fig. 4C) . These results demonstrated that STAT3/Twist signaling mediated the BrMC-induced inhibition of the stemness of LCSLCs originated from HCC SMMC-7721 cell line.
Discussion
Spheroid cultures have been used to propagate potential CSC subpopulations in HCC [4, 18, 19] . LCSLCs generate spheroids cells with potential for self-renewal and tumorigenicity [4] . Clonally unattached tumor spheroids derived from HCC cell lines cultured in stem cellconditioned medium exhibit stem cell features [4] . In the present study, we found that the dissociated first-generation spheroids of SMMC-7721 cell line generate second-generation spheroids, and subsequently third-, fourth-, and fifth-generation spheroids. They were passaged >10 times, indicating that a substantial proportion of single cells derived from the spheroids were self-renewing cells that can be propagated in culture as LCSLCs. We previously reported that BrMC significantly inhibited the self-renewal, EMT, and invasion by liver CSCs from HCC cell lines in vitro, and suppressed carcinogenesis in a xenograft model of BALB/c nu mouse [11, 12] . In the present study, we demonstrated that low concentrations of BrMC effectively decreased spheroid formation, and cell migration. BrMC also suppressed the expressions of CSC proteins (CD133, CD44, and ALDH1) in LCSLCs derived from HCC SMMC-7721 cells in vitro.
STAT3 is a transcription factor involved in cytokine signaling. It is abnormally activated in cancers of prostate, breast, brain, and lung [20] [21] [22] [23] . Tumor-associated macrophages secrete IL-6 via STAT3-mediated signaling to induce the proliferation of HCC stem cells [24] . ChR promoted TRAIL-induced cancer cell apoptosis by inhibiting STAT3 phosphorylation in the presence of STAT3-specific inhibitor, JSI-124 [25] . In addition, Lin et al. [26] reported that ChR inhibited IL-6-induced angiogenesis in cancers via STAT3 signaling. We recently reported that BrMC inhibited STAT3 activation to abolish stem cell-like characteristics in SMMC-7721 cells [5] . In this study, we found that a combination of JSI-124 and BrMC cooperatively reduced spheroid formation and cell migration, as well as down-regulated the expressions of CD133, CD44, and ALDH1, along with p-STAT3 in vitro, suggesting that BrMC inhibited STAT3 activity of LCSLCs.
Twist1 plays a key role in the development of mesodermal tissues [13] [14] [15] 27] . During mouse embryogenesis, Twist1 is highly expressed in mesodermal tissues including neural crest-derived mesenchyme, branchial arch, muscle, bone, and fibroblasts [28, 29] . However, Twist1 is known to be an important inducer of EMT and Twist1 overexpression in cancer cells is correlated with poor prognosis [30] [31] [32] . We recently demonstrated that BrMC inhibited proliferation and invasion of stem cells in liver cancer, down-regulated the expressions of CD133 and CD44, and reverse EMT by suppressing Twist1 [11] . In this study, we showed that Twist1 gene transduction triggered spheroid formation, cell migration, and the expressions of CD133, CD44, ALDH1, and Twist1, and significantly attenuated BrMC inhibition. These results further validate the role of BrMC in the stemness of LCSLCs via down-regulation of Twist1 expression.
Transcription factors STAT3 and Twist regulate cancer development and are critical regulators of gastric cancer formation and progression [33] . Cheng et al. [17] reported that STAT3 activated the transcription of Twist promoter. Twist rescued the carcinogenic manifestations following inhibition of STAT3. Therefore, STAT3 and Twist1 constitute a signaling axis to regulate carcinogenesis. In the present study, we demonstrated that ectopic expression of Twist1 attenuated the inhibitory effects of BrMC (0.1 μM) on spheroid formation, motility and migration, as well as the expressions of markers CD133, CD44, and ALDH1, as well as Twist1 in LCSLCs. However, it had no effect on the expression of p-STAT3. To the best of our knowledge, this is the first report demonstrating that BrMC inhibited the stemness of SMMC-7721-derived LCSLCs by interfering with the STAT3/Twist signal axis.
In conclusion, we demonstrated that BrMC-blocked STAT3/ Twist signal axis inhibits CSC-like features of SMMC-7721 spheroids. This study represents a crucial line of evidence supporting the role of BrMC in LCSLCs. It facilitates the design of novel therapeutic interventions for HCC.
